Renal cell carcinoma may evade the immune system by converting CD4 +Foxp3- T cells into CD4+CD25 +Foxp3+ regulatory T cells: Role of tumor COX-2-derived PGE2

Molecular Medicine Reports

Volumn 3, Issue 6, 2010, Pages 959-963

  Li, Jinfeng ^a,c   Feng, Guiwen ^a   Liu, Jia ^b   Rong, Ruiming ^c   Luo, Feifei ^c   Guo, Liang ^c   Zhu, Tongyu ^c   Wang, Guomin ^c   Chu, Yiwei ^c  

^a ZHENGZHOU UNIVERSITY   (China)

^b Henan Medical Workers College   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

COX 2; Prostaglandin E2; Regulatory T cells; Renal cell carcinoma

Indexed keywords

CYCLOOXYGENASE 2; PROSTAGLANDIN E2;

ARTICLE; CD4+ CD25+ FOXP3+ T LYMPHOCYTE; CD4+ FOXP3+ T LYMPHOCYTE; CELL CULTURE; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SUPERNATANT; TUMOR ESCAPE;

EID: 78649493352     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2010.374     Document Type: Article

References (18)

1. Amato RJ: Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16: 7-15, 2005.
2. Sanchez-Ortiz RF, Tannir N, Ahrar K and Wood CG: Spontaneous regression of pulmonary metastases from renal cell carcinoma after radiofrequency ablation of the primary tumor: an in situ tumor vaccine? J Urol 170: 178-179, 2003.
3. - thymocytes. J Exp Med 189: 279-288, 1999.
4. Asseman C, Mauze S, Leach MW, Coffman RL and Powrie F: An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190: 995-1004, 1999.
5. - regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25: 207-217, 2002.
6. + regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 32: 3267-3275, 2002.
7. Griffiths RW, Elkord E, Gilham DE, et al: Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 56: 1743-1753, 2007.
8. Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T and Kanetake H: Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 9: 1741-1749, 2003.
9. Hashimoto Y, Kondo Y, Kimura G, et al: Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma. Histopathology 44: 353-359, 2004.
10. - T regulatory cell activities in lung cancer. Cancer Res 65: 5211-5220, 2005.
11. Li JF, Chu YW, Wang GM, et al: The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral COX-2 expression in clear cell renal cell carcinoma. BJU Int 103: 399-405, 2009.
12. Curiel TJ, Coukos G, Zou L, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949, 2004.
13. - regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24: 1169-1177, 2006.
14. Dannull J, Su Z, Rizzieri D, et al: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115: 3623-3633, 2005.
15. + regulatory T cells. Immunology 109: 319-325, 2003.
16. Bluestone JA and Abbas AK: Natural versus adaptive regulatory T cells. Nat Rev Immunol 3: 253-257, 2003.
17. Liyanage UK, Moore TT, Joo HG, et al: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761, 2002.
18. - regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98: 1089-1099, 2003.